The Institute for Global Health is currently seeking participants with HIV, who are being treated with Trogarzo (Ibalizumab). This registry study will look at routine healthcare data for 3 years to see how effective and long lasting Trogarzo is, when used in combination with other drugs used to treat adults living with HIV, who have tried multiple HIV medications. No study medications will be administered and no medical procedures will be performed as part of this study. All study information will be collected as part of your routine healthcare.

The Institute for Global Health is enrolling participants, aged 18-70, who are living with HIV and on stable ART (antiretroviral treatment). The purpose of this study is to test two investigational drugs, budigalmab and ABBV-382 and learn what kinds of side effects or other safety problems might be seen when the combination is given. Also to learn if budigalimab and/or ABBV-382 can help the body control the HIV viral load after ART has been stopped. Your participation in this study may include approximately 17 study visits to the research center and 8 phone call visits. The study duration is approximately 57 weeks.

The Institute for Global Health is currently seeking participants who are 18-64 years of age for an Influenza Registry study. This is a Registry of healthy adults who would be potentially eligible for future vaccine studies.   This study is recruiting healthy adults to gather vaccination history, history of recent infections and collect blood at multiple time points to understand their immunity.

This is an expanded use protocol for patients diagnosed with a Mycobacterium avium complex (MAC). Sponsored by Novartis, the purpose of this program is to make clofazimine available to appropriate patients following clinical presentation.